R^2 is selected from -H, -halo and -C_{1-3}alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3. In one embodiment, R^2 is -H. In another embodiment, R^2 is -halo. In one embodiment, R^2 is -F. In another embodiment, R^2 is -C_{1-3}alkyl. In one embodiment, R^2 is methyl.

R^3 is selected from -H; -C_{1-6}alkyl; -C_{2-6}alkenyl; -C_{2-6}alkynyl; -C_{3-7}cycloalkyl; and a 5 or 6 membered heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl are optionally substituted by 1, 2 or 3 groups, for example 1 or 2 groups, selected from -C_{1-3}alkyl optionally substituted with 1, 2 or 3 substituents selected from -F, -CF_3, -C(O)$NR^8R^9$and -NR^8R^9.

In one embodiment, R^3 is selected from -H; -C_{2-4}alkynyl; -C_{1-3}alkyl optionally substituted with -C(O)NR^8R^9 or -NR^8R^9; and a 5 or 6 membered heterocycloalkyl optionally substituted with C_{1-3}alkyl.

In one embodiment, R^3 is selected from -H; -C_{2-4}alkynyl; -C_{1-3}alkyl optionally substituted with -C(O)NR^8R^9 or -NR^8R^9; and a 5 or 6 membered nitrogen containing heterocycloalkyl optionally substituted with C_{1-3}alkyl.

In one embodiment, R^3 is selected from -H; -C_{2-4}alkynyl; -C_{1-3}alkyl optionally substituted with -C(O)NR^8R^9 or -NR^8R^9; and piperidinyl optionally substituted with C_{1-3}alkyl.

In one embodiment, R^3 is selected from methyl, ethyl, *i*-propyl, -$(CH_2)_2N(CH_3)_2$, -$(CH_2)_3N(CH_3)_2$, -$CH_2C{\equiv}CH$, -$CH_2C(O)N(CH_3)_2$ and N-methylpiperidine. In one embodiment, R^3 is selected from ethyl, *i*-propyl, -$(CH_2)_2N(CH_3)_2$, -$(CH_2)_3N(CH_3)_2$, -$CH_2C{\equiv}CH$, -$(CH_2)_2C(O)N(CH_3)_2$ and N-methylpiperidine.

In one embodiment, R^3 is selected from -C_{2-4}alkynyl and -C_{1-3}alkyl optionally substituted with -NR^8R^9.

In one embodiment, R^3 is selected from ethyl, *i*-propyl, -$(CH_2)_2N(CH_3)_2$, -$(CH_2)_3N(CH_3)_2$ and -$CH_2C{\equiv}CH$.

In one embodiment, R^3 is *i*-propyl.

R^{4a} and R^{4b} are each independently selected from -H and -C_{1-3}alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3. In one embodiment, R^{4a} is methyl and R^{4b} is -H. In one embodiment, R^{4a} and R^{4b} are both -H.

R^{4c} and R^{4d} are each independently selected from -H and C_{1-3} alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3; or R^{4c} and R^{4d} together with the carbon to which they are attached represent carbonyl. In one embodiment, R^{4c} and R^{4d} together with the carbon to which they are attached represent carbonyl. In another embodiment, R^{4c} and R^{4d} are each independently selected from -H and C_{1-3} alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3. In another embodiment, R^{4c} and R^{4d} are both -H or together with the carbon to which they are attached represent carbonyl. In yet another embodiment, R^{4c} and R^{4d} are both -H.

R^{5a}, R^{5b}, R^{5c} and R^{5d} are each independently selected from -H and -C_{1-3} alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3. In one embodiment, R^{5a}, R^{5b}, R^{5c} and R^{5d} are each independently selected from -H and -C_{1-3} alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3. In one embodiment, R^{5a}, R^{5b}, R^{5c} and R^{5d} are each independently selected from -H and -C_{1-3} alkyl. In one embodiment, R^{5a} is methyl and R^{5b}, R^{5c} and R^{5d} are each -H. In one embodiment, R^{5a}, R^{5b} and R^{5c} are each -H and R^{5d} is methyl. In one embodiment, R^{5a}, R^{5b}, R^{5c} and R^{5d} each represent -H.

R^6 is selected from -H; -halo; -NH_2; -CN; -C_{1-3}alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and CF_3; -C_{1-3}alkoxy optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3; -C(O)O-C_{1-3}alkyl; -C(O)NR^8R^9; -C(O)OH; and -NHC(O)-C_{1-3}alkyl. In one embodiment, R^6 is selected from -H; -Br; -NH_2; -CN; methoxy; ethyl; -C(O)OCH_3; -C(O)NH_2; -C(O)OH; and -NHC(O)CH_3.

R^7 is selected from -$NR^{10}R^{11}$; a 5 to 7 membered monocyclic heterocycloalkyl; and a 5 or 6 membered monocyclic heteroaryl; wherein the heterocycloalkyl and heteroaryl are optionally substituted with 1, 2 or 3 (for example, 1 or 2) groups selected from -CN; -C_{1-6}alkyl optionally substituted with 1, 2 or 3 substituents selected from -F, -CF_3 and -OH; -C_{1-3}alkoxy optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3; -C(O)OH; -C_{1-3}alkylene-NHC(O)C_{1-6}alkyl; -C_{1-3}alkylene-NHC(O)OC_{1-6}alkyl; and C_{3-5}cycloalkyl; or the heterocycloalkyl is optionally substituted with two substituents on the same ring carbon which together with the carbon atom to which they are attached form a 5 to 7 membered monocyclic heterocycloalkyl.

In one embodiment, R^7 is selected from $NR^{10}R^{11}$; a 5 to 7 membered monocylic heterocycloalkyl selected from morpholinyl, thiazolidinyl, tetrahydropyranyl, dihydropyranyl, thiomorpholinyl and 3,4-dihydro-2H-pyranyl; a 5 or 6 membered monocyclic heteroaryl selected from pyridinyl, pyrrolyl, oxazolyl, imidazolyl and thiazolyl; wherein the heterocycloalkyl and heteroaryl are optionally substituted with 1, 2 or 3 (for example, 1 or 2) groups selected from -CN; -C_{1-6}alkyl optionally substituted with 1, 2 or 3 substituents selected from -F, -CF_3 and -OH; -C_{1-3}alkoxy optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3; -C(O)OH; -C_{1-3}alkylene-NHC(O)C_{1-6}alkyl; -C_{1-3}alkylene-NHC(O)OC_{1-6}alkyl; and C_{3-5}cycloalkyl; or the heterocycloalkyl is optionally substituted with two substituents on the same ring carbon which together with the carbon atom to which they are attached form a 5 to 7 membered monocyclic heterocycloalkyl.

In one embodiment, R^7 is selected from $NR^{10}R^{11}$; a 5 to 7 membered monocylic heterocycloalkyl selected from morpholinyl, thiazolidinyl, tetrahydropyranyl, dihydropyranyl, thiomorpholinyl and 3,4-dihydro-2H-pyranyl; a 5 or 6 membered monocyclic heteroaryl selected from pyridinyl, pyrrolyl, oxazolyl, imidazolyl and thiazolyl; wherein the heterocycloalkyl and heteroaryl are optionally substituted with 1, 2 or 3 (for example, 1 or 2) groups selected from -CN, methyl, ethyl, propyl, cyclopropyl, methoxy, -CH_2CF_3, -CH_2OH, -CH_2CH_2OH, -C(O)OH, -$(CH_2)_2NHC(O)CH_3$ and -$CH_2NHC(O)OC(CH_3)_3$; or the heterocycloalkyl is optionally substituted with two substituents on the same ring carbon which together with the carbon atom to which they are attached form a 6 membered monocyclic heterocycloalkyl.

In one embodiment, R^7 is selected from $NR^{10}R^{11}$ wherein R^{10} is selected from methyl, ethyl or propyl and R^{11} is selected from ethyl, propyl, CH_2CHF_2, $CH_2CH_2OCH_2CH_3$ and $–(CH_2)_pR^{12}$; a 5 to 7 membered monocyclic heterocycloalkyl selected from morpholinyl, thiazolidinyl, tetrahydropyranyl, dihydropyranyl,

thiomorpholinyl and 3,4-dihydro-2H-pyranyl; a 5 or 6 membered monocyclic heteroaryl selected from pyridinyl, pyrrolyl, oxazolyl, imidazolyl and thiazolyl; wherein the heterocycloalkyl and heteroaryl are optionally substituted with 1 or 2 groups selected from -CN, methyl, ethyl, propyl, cyclopropyl, methoxy, -CH_2CF_3, -CH_2OH, -CH_2CH_2OH, -C(O)OH, -$(CH_2)_2NHC(O)CH_3$ and -$CH_2NHC(O)OC(CH_3)_3$; or the heterocycloalkyl is optionally substituted with two substituents on the same ring carbon which together with the carbon atom to which they are attached form tetrahydropyranyl.

In one embodiment, R^7 is selected from $NR^{10}R^{11}$ wherein R^{10} is selected from methyl, ethyl or propyl and R^{11} is selected from ethyl, propyl, CH_2CHF_2, $CH_2CH_2OCH_2CH_3$ and $–(CH_2)_nR^{12}$.

In one embodiment, R^7 is selected from $NR^{10}R^{11}$ wherein R^{10} is selected from methyl, ethyl or propyl; R^{11} is selected from ethyl, propyl, CH_2CHF_2, $CH_2CH_2OCH_2CH_3$ and $–(CH_2)_nR^{12}$; n is 1 or 2; and R^{12} is selected from isoxazolyl, oxadiazolyl, cyclopropyl, pyrazinyl, tetrahydrofuranyl and pyridinyl.

In one embodiment, R^7 is selected from a 5 to 7 membered monocyclic heterocycloalkyl optionally substituted with 1, 2 or 3 (for example, 1 or 2) groups selected from -CN; -$C_{1\text{-}6}$alkyl optionally substituted with 1, 2 or 3 substituents selected from -F, -CF_3 and -OH; -$C_{1\text{-}3}$alkoxy optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3; -C(O)OH; --$C_{1\text{-}3}$alkylene-NHC(O)$C_{1\text{-}6}$alkyl; -$C_{1\text{-}3}$alkylene-NHC(O)$OC_{1\text{-}6}$alkyl and $C_{3\text{-}5}$cycloalkyl; or the heterocycloakyl is optionally substituted with two substituents on the same ring carbon which together with the carbon atom to which they are attached form a 5 to 7 membered monocyclic heterocycloalkyl.

In one embodiment, R^7 is a 5 to 7 membered monocyclic heterocycloalkyl selected from morpholinyl, thiazolidinyl, tetrahydropyranyl, pyrrolyl, thiomorpholinyl and 3,4-dihydro-2H-pyranyl wherein the heterocycloalkyl is optionally substituted with 1 or 2 groups selected from -CN; -$C_{1\text{-}6}$alkyl optionally substituted with 1, 2 or 3 substituents selected from -F, -CF_3 and -OH; -$C_{1\text{-}3}$alkoxy optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3; -C(O)OH; -$CH_2NHC(O)CH_3$; -$CH_2NHC(O)OC(CH_3)_3$; and $C_{3\text{-}5}$cycloalkyl; or the heterocycloalkyl is optionally substituted with two substituents on the same ring carbon which together with the carbon atom to which they are attached form a 6 membered monocyclic heterocycloalkyl;

In one embodiment, R^7 is a 5 to 7 membered monocyclic heterocyclalkyl optionally substituted with 1 or 2 substituents selected from methyl, ethyl, propyl, cyclopropyl, -CH_2CH_2OH, -CH_2OH, -C(O)OH, -CH_2CF_3, and - $CH_2NHC(O)OC(CH_3)_3$; or the heterocycloalkyl is optionally substituted with two substituents on the same ring carbon which together with the carbon atom to which they are attached form tetrahydropyran.

In one embodiment, R^7 is morpholinyl optionally substituted with 1 or 2 substituents selected from methyl, ethyl, propyl, cyclopropyl, -CH_2CH_2OH, -CH_2OH, -C(O)OH, -CH_2CF_3, and - $CH_2NHC(O)OC(CH_3)_3$; or optionally substituted with two substituents on the same ring carbon which together with the carbon atom to which they are attached form tetrahydropyran (*i.e.* R^7 becomes a spirocyclic group).

In one embodiment, R^7 is 2-methylmorpholin-4-yl.

Claims

1. A compound of Formula (I):



(I)

R^1 is selected from C_{2-6}alkyl; C_{2-6}alkenyl; C_{2-6}alkynyl; C_{2-6}alkoxy; C_{2-6}alkenyloxy; C_{2-6}alkynyloxy; C_{3-7}cycloalkyl; -O-C_{3-7}cycloalkyl; C_{6-10}aryl; -O-$(CH_2)_m$-C_{6-10}aryl; 6 membered heteroaryl; and thiophenyl; wherein alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyl are optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3 and wherein aryl and heteroaryl are optionally substituted with 1 or 2 substituents selected from -halo, -C_{1-3}alkyl, -C_{1-8}alkoxy and -C_{2-8}alkynyloxy wherein -C_{1-3}alkyl, -C_{1-8}alkoxy and -C_{2-8}alkynyloxy are optionally substituted with 1, 2, or 3 substituents selected from -F, -CF_3 and -NHC(O)O-C_{1-6}alkyl or two substituents together with the carbon to which they are attached form diazirinyl;

R^2 is selected from -H; -halo; and -C_{1-3}alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3;

A is selected from:



; and or a N-oxide thereof;

R^3 is selected from -H; -C_{1-6}alkyl; -C_{2-6}alkenyl; -C_{2-6}alkynyl; -C_{3-7}cycloalkyl; and a 5 or 6 membered heterocycloalkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl are optionally substituted by 1, 2 or 3 groups selected from -F, -CF_3, -C_{1-3}alkyl optionally substituted by 1 or 2 substituents selected from -F, -CF_3, -C(O)NR^8R^9 and -NR^8R^9;

R^{4a} and R^{4b} are each independently selected from -H and -C_{1-3} alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3;

R^{4c} and R^{4d} are each independently selected from -H and -C_{1-3} alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and CF_3; or R^{4c} and R^{4d} together with the carbon to which they are attached represent carbonyl;

R^{5a}, R^{5b}, R^{5c} and R^{5d} are each independently selected from -H and -C_{1-3} alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and CF_3;

R^6 is selected from -H; -halo; -NH_2; -CN; -C_{1-3}alkyl optionally substituted with 1, 2 or 3 substituents selected from -F and CF_3; -C_{1-3}alkoxy optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3; -C(O)O-C_{1-3}alkyl; -C(O)NR^8R^9; -C(O)OH; and -NHC(O)-C_{1-3}alkyl;

R^7 is selected from $NR^{10}R^{11}$; a 5 to 7 membered monocyclic heterocycloalkyl; and a 5 or 6 membered monocyclic heteroaryl; wherein the heterocycloalkyl and heteroaryl are optionally substituted with 1, 2 or 3 groups selected from -CN; -C_{1-6}alkyl optionally substituted with 1, 2 or 3 substituents selected from -F, -CF_3 and -OH; -C_{1-3}alkoxy optionally substituted with 1, 2 or 3 substituents selected from -F and CF_3; -C(O)OH; -C_{1-3}alkylene-NHC(O)C_{1-6}alkyl; -C_{1-3}alkylene-NHC(O)OC_{1-6}alkyl; and C_{3-5}cycloalkyl; or the heterocycloalkyl is optionally substituted with two substituents on the same ring carbon which together with the carbon atom to which they are attached form a 5 to 7 membered monocyclic heterocycloalkyl; and wherein when R^7 is morpholinyl and R^1 is unsubstituted phenyl, R^2 is not -H;

R^8 and R^9 are each independently selected from -H and -C_{1-6}alkyl;

R^{10} is -C_{1-6}alkyl;

R^{11} is selected from -C_{1-6}alkyl optionally substituted with 1 or 2 substituents selected from -F and -C_{1-3}alkoxy; and -$(CH_2)_nR^{12}$;

R^{12} is a 5 or 6 membered heteroaryl, a 3 to 5 membered cycloalkyl or a 3 to 6 membered heterocycloalkyl;

m is 0 or 1; and

n is 1, 2 or 3.

2. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1,



wherein A is and R^3, R^{4a}, R^{4b}, R^{4c} and R^{4d} are as defined in claim 1.

3. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein A is  and R^{5a}, R^{5b}, R^{5c} and R^{5d} are as defined in claim 1.

4. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein A is  or a N-oxide thereof and R^6 is as defined in claim 1.

5. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein R^1 is selected from C_{2-6}alkyl; C_{2-6}alkoxy; C_{3-7}cycloalkyl; -O-C_{3-7}cycloalkyl; C_{6-10}aryl; -O-$(CH_2)_m$-C_{6-10}aryl; and thiophenyl, wherein the alkyl, alkoxy and cycloalkyl are optionally substituted with 1, 2 or 3 substituents selected from -F and -CF_3 and wherein aryl is optionally substituted with 1 or 2 substituents selected from -halo, -C_{1-3}alkyl, -C_{1-8}alkoxy and -C_{2-8}alkynyloxy wherein -C_{1-3}alkyl, -C_{1-8}alkoxy and -C_{2-8}alkynyloxy are optionally substituted with 1, 2, or 3 substituents selected from -F, -CF_3 and -NHC(O)O-C_{1-6}alkyl or two substituents together with the carbon to which they are attached form diazirinyl.

6. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein R^1 is selected from -CH_2CF_3; -CF_2CF_3; propyl; butyl; pentyl; propoxy; cyclobutyl; cyclohexyl; -O-cyclopentyl; phenyl optionally substituted with 1 or 2 substituents selected from -F, -Cl, -CH_3, -O-$(CH_2)_5C{\equiv}CH$, -O-$(CH_2)_7$, -O-$(CH_2)_2C(N{=}N)(CH_2)_2C{\equiv}CH$, -O-$(CH_2)_2NHC(O)OC(CH_3)_3$, -O-$CH_2C{\equiv}CH$, -O-$(CH_2)_5CF_3$ and -O-$(CH_2)_7$; -O-phenyl optionally substituted with -F; -O-CH_2-phenyl and thiophenyl.

7. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein R^2 is -H, -F or methyl.

8. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 2 and 5 to 7, wherein R^3 is ethyl, *i*-propyl, propynyl, -$CH_2C{\equiv}CH$, -$(CH_2)_2N(CH_3)_2$, -$(CH_2)_3N(CH_3)_2$, -$(CH_2)_2C(O)N(CH_3)_2$ or N-methylpiperidine.

9. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 2 and 5 to 8, wherein R^{4a} and R^{4b} are both -H.

10. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 2 and 5 to 9, wherein R^{4d} and R^{4c} together with the carbon to which they are attached represent carbonyl.

11. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1, 3 and 5 to 7, wherein R^{5a}, R^{5b}, R^{5c} and R^{5d} are each -H.

12. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any of claims 1, 4 and 5 to 7, wherein R^6 is selected from -H, -Br, $-NH_2$, -CN, methoxy, ethyl, $-C(O)OCH_3$, $-C(O)NH_2$, -C(O)OH and $-NHC(O)CH_3$.

13. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein R^7 is a 5 to 7 membered monocylic heterocycloalkyl selected from morpholinyl, thiazolidinyl, tetrahydropyranyl, dihydropyranyl, thiomorpholinyl and 3,4-dihydro-2H-pyranyl; a 5 or 6 membered monocyclic heteroaryl selected from pyridinyl, pyrrolyl, oxazolyl, imidazolyl and thiazolyl; wherein the heterocycloalkyl and heteroaryl are optionally substituted with 1, 2 or 3 groups selected from -CN; $-C_{1\text{-}6}$alkyl optionally substituted with 1, 2 or 3 substituents selected from -F, $-CF_3$ and -OH; $-C_{1\text{-}3}$alkoxy optionally substituted with 1, 2 or 3 substituents selected from -F and $-CF_3$; -C(O)OH; $-C_{1\text{-}3}$alkylene-$NHC(O)C_{1\text{-}6}$alkyl; $-C_{1\text{-}3}$alkylene-$NHC(O)OC_{1\text{-}6}$alkyl; and $C_{3\text{-}5}$cycloalkyl; or the heterocycloalkyl is optionally substituted with two substituents on the same ring carbon which together with the carbon atom to which they are attached form a 5 to 7 membered monocyclic heterocycloalkyl.

14. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any preceding claim, wherein R^7 is a 5 to 7 membered monocylic heterocycloalkyl selected from morpholinyl, thiazolidinyl, tetrahydropyranyl, dihydropyranyl, thiomorpholinyl and 3,4-dihydro-2H-pyranyl; a 5 or 6 membered monocyclic heteroaryl selected from pyridinyl, pyrrolyl, oxazolyl, imidazolyl and thiazolyl; wherein the heterocycloalkyl and heteroaryl are optionally substituted with 1, 2 or 3 groups selected from -CN, methyl, ethyl, propyl, cyclopropyl, methoxy, $-CH_2CF_3$, $-CH_2OH$, $-CH_2CH_2OH$, -C(O)OH, $-(CH_2)_2NHC(O)CH_3$ and $-CH_2NHC(O)OC(CH_3)_3$; or the heterocycloalkyl is optionally substituted with two substituents on the same ring carbon which together with the carbon atom to which they are attached form a tetrahydropyranyl.

15. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 12, wherein R^7 is $NR^{10}R^{11}$.

16. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1, 2, 4 to 10 and 12 to 15, wherein R^8 and R^9 are either both -H or are both methyl.

17. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed any one of claims 1 to 12, 15 and 16, wherein R^{10} is selected from methyl, ethyl and propyl.

18. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 12 and 15 to 17, wherein R^{11} is selected from ethyl, $-CH_2CHF_2$, propyl, $-(CH_2)_2O(CH_2)_2$ and $-(CH_2)_nR^{12}$.

19. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any of claims 1 to 12 and 15 to 18, wherein R^{12} is selected from isoxazolyl, oxadiazolyl, cyclopropyl, pyrazinyl, tetrahydrofuranyl and pyridinyl.

20. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (II), or a pharmaceutically acceptable salt thereof:



(II)

wherein R^1, R^2, R^3, R^{4a}, R^{4b} and R^7 as defined for Formula (I) in claim 1.

21. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (III), or a pharmaceutically acceptable salt thereof:



(III)

wherein R^1, R^2, R^{5a}, R^{5b}, R^{5c}, R^{5d} and R^7 are as defined in claim 1.

22. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (IV), or N-oxide or pharmaceutically acceptable salt thereof:



(IV)

wherein R^1, R^2, R^6 and R^7 are as defined for Formula (I) in claim 1.

23. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein the compound is selected from the group consisting of:

2-(diethylamino)-6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(2-cyclopropylmorpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-2-(1,3-thiazolidin-3-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-2-(thiomorpholin-4-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-[(2S)-2-methylmorpholin-4-yl]-6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-[(2R)-2-methylmorpholin-4-yl]-6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-[(2S,6S)-2,6-dimethylmorpholin-4-yl]-6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(3-methylmorpholin-4-yl)-6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(2-cyclopropylmorpholin-4-yl)-6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(morpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(2-methylmorpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-[(2R)-2-methylmorpholin-4-yl]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-((2R)-cyclopropylmorpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-((2S)-cyclopropylmorpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-6-(propan-2-yl)-2-[2-(2,2,2-trifluoroethyl)morpholin-4-yl]-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

tert-butyl {[(2R)-4-{4-[(4-cyclohexylphenyl)amino]-7-oxo-6-(propan-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl}morpholin-2-yl]methyl}carbamate;

4-[(4-cyclohexylphenyl)amino]-6-(propan-2-yl)-2-[2-(propan-2-yl)morpholin-4-yl]-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-6-(propan-2-yl)-2-(1,3-thiazolidin-3-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-[(2-ethoxyethyl)(methyl)amino]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(2-ethylmorpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-{methyl[(1,2-oxazol-3-yl)methyl]amino}-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-{methyl[2-(1,2,4-oxadiazol-3-yl)ethyl]amino}-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(1,4-oxazepan-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(1,9-dioxa-4-azaspiro[5.5]undecan-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(3-methoxypyrrolidin-1-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-[2-(2-hydroxyethyl)morpholin-4-yl]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(dipropylamino)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-[(cyclopropylmethyl)(methyl)amino]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-[2-(hydroxymethyl)morpholin-4-yl]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-[3-(hydroxymethyl)morpholin-4-yl]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-{methyl[(pyrazin-2-yl)methyl]amino}-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(diethylamino)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-{methyl[(oxolan-2-yl)methyl]amino}-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-[(2,2-difluoroethyl)(methyl)amino]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-{methyl[2-(pyridin-2-yl)ethyl]amino}-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

(3S)-4-{4-[(4-cyclohexylphenyl)amino]-7-oxo-6-(propan-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl}morpholine-3-carboxylic acid;

N-[2-(4-{4-[(4-cyclohexylphenyl)amino]-7-oxo-6-(propan-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl}morpholin-2-yl)ethyl]acetamide;

6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-2-(pyridin-4-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-{4-[(4-cyclohexylphenyl)amino]-7-oxo-6-(propan-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl}pyridine-2-carbonitrile;

4-[(4-cyclohexylphenyl)amino]-2-(2-cyclopropylpyridin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(2-methoxypyridin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(2-methylpyridin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(3,6-dihydro-2H-pyran-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-6-(propan-2-yl)-2-(pyridin-4-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(1-methyl-1H-pyrazol-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(1,3-oxazol-5-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-6-(propan-2-yl)-2-(1,3-thiazol-5-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(3,6-dihydro-2H-pyran-4-yl)-6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-{[4-(4-fluorophenoxy)phenyl]amino}-2-[(2R)-2-methylmorpholin-4-yl]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(2-cyclopropylmorpholin-4-yl)-4-({4'-[(hept-6-yn-1-yl)oxy][1,1'-biphenyl]-4-yl}amino)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(2-cyclopropylmorpholin-4-yl)-4-{[4'-(heptyloxy)[1,1'-biphenyl]-4-yl]amino}-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4'-{2-[3-(but-3-yn-1-yl)-3H-diaziren-3-yl]ethoxy}[1,1'-biphenyl]-4-yl)amino]-2-(2-cyclopropylmorpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-[(2R)-2-methylmorpholin-4-yl]-4-[(4-pentylphenyl)amino]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-{[4-(butan-2-yl)phenyl]amino}-2-[(2R)-2-methylmorpholin-4-yl]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-{[4-(benzyloxy)phenyl]amino}-2-[(2R)-2-methylmorpholin-4-yl]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(2-cyclopropylmorpholin-4-yl)-4-{[4-(pentafluoroethyl)phenyl]amino}-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(2-cyclopropylmorpholin-4-yl)-6-(propan-2-yl)-4-[(4-propylphenyl)amino]-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-[(2R)-2-methylmorpholin-4-yl]-6-(propan-2-yl)-4-[(4-propylphenyl)amino]-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-[(2R)-2-methylmorpholin-4-yl]-4-{[4-(pentafluoroethyl)phenyl]amino}-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(2-cyclopropylmorpholin-4-yl)-6-(propan-2-yl)-4-({4-[(propan-2-yl)oxy]phenyl}amino)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclobutylphenyl)amino]-2-(morpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-{[4-(cyclopentyloxy)phenyl]amino}-2-[(2R)-2-methylmorpholin-4-yl]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-[(2R)-2-methylmorpholin-4-yl]-6-(propan-2-yl)-4-{[4-(2,2,2-trifluoroethyl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

tert-butyl {2-[(4'-{[2-(2-cyclopropylmorpholin-4-yl)-7-oxo-6-(propan-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl]amino}[1,1'-biphenyl]-4-yl)oxy]ethyl}carbamate;

6-ethyl-2-[(2R)-2-methylmorpholin-4-yl]-4-{[4-(propan-2-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-6-ethyl-2-[(2R)-2-methylmorpholin-4-yl]-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

tert-butyl {2-[(4'-{[2-(morpholin-4-yl)-7-oxo-6-(propan-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl]amino}[1,1'-biphenyl]-4-yl)oxy]ethyl}carbamate;

4-[(4'-{2-[3-(but-3-yn-1-yl)-3H-diaziren-3-yl]ethoxy}[1,1'-biphenyl]-4-yl)amino]-2-(morpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(morpholin-4-yl)-6-(propan-2-yl)-4-({4'-[(prop-2-yn-1-yl)oxy][1,1'-biphenyl]-4-yl}amino)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-6-[3-(dimethylamino)propyl]-2-[(2R)-2-methylmorpholin-4-yl]-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-6-[2-(dimethylamino)ethyl]-2-[(2R)-2-methylmorpholin-4-yl]-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclobutylphenyl)amino]-6-[3-(dimethylamino)propyl]-2-[(2R)-2-methylmorpholin-4-yl]-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclobutylphenyl)amino]-6-[2-(dimethylamino)ethyl]-2-[(2R)-2-methylmorpholin-4-yl]-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(morpholin-4-yl)-4-{[4-(propan-2-yl)phenyl]amino}-6-(prop-2-yn-1-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(oxan-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-cyclohexylphenyl)amino]-2-(1H-imidazol-1-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(3,6-dihydro-2H-pyran-4-yl)-4-[(2'-methyl[1,1'-biphenyl]-4-yl)amino]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4'-{2-[3-(but-3-yn-1-yl)-3H-diaziren-3-yl]ethoxy}[1,1'-biphenyl]-4-yl)amino]-2-(3,6-dihydro-2H-pyran-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(3,6-dihydro-2H-pyran-4-yl)-4-[(2-fluoro[1,1'-biphenyl]-4-yl)amino]-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(morpholin-4-yl)-4-{[4-(pentafluoroethyl)phenyl]amino}-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(2-fluoro[1,1'-biphenyl]-4-yl)amino]-2-(morpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(3',4'-dichloro[1,1'-biphenyl]-4-yl)amino]-2-(morpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

2-(morpholin-4-yl)-6-(propan-2-yl)-4-{[4-(propan-2-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4-tert-butylphenyl)amino]-2-(morpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(2-methyl[1,1'-biphenyl]-4-yl)amino]-2-(morpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

4-[(4'-chloro[1,1'-biphenyl]-4-yl)amino]-2-(morpholin-4-yl)-6-(propan-2-yl)-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one;

N-(4-cyclohexylphenyl)-2-[(2R)-2-methylmorpholin-4-yl]-5,7-dihydrofuro[3,4-d]pyrimidin-4-amine;

N-(4-cyclobutylphenyl)-2-(3,6-dihydro-2H-pyran-4-yl)-5,7-dihydrofuro[3,4-d]pyrimidin-4-amine;

N-(4-cyclohexylphenyl)-2-(2-cyclopropylmorpholin-4-yl)-5,7-dihydrofuro[3,4-d]pyrimidin-4-amine;

2-(2-cyclopropylmorpholin-4-yl)-N-[4'-(heptyloxy)[1,1'-biphenyl]-4-yl]-5,7-dihydrofuro[3,4-d]pyrimidin-4-amine;

2-[(2R)-2-methylmorpholin-4-yl]-N-{4'-[(6,6,6-trifluorohexyl)oxy][1,1'-biphenyl]-4-yl}-5,7-dihydrofuro[3,4-d]pyrimidin-4-amine;

N-(4-cyclohexylphenyl)-2-(2-methylpyridin-4-yl)-5,7-dihydrofuro[3,4-d]pyrimidin-4-amine;

N-(4-cyclohexylphenyl)-2-[(2R)-2-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-4-amine;

6-bromo-N-(4-cyclohexylphenyl)-2-[(2R)-2-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-4-amine;

N-(4-cyclohexylphenyl)-2-(3,6-dihydro-2H-pyran-4-yl)pyrido[2,3-d]pyrimidin-4-amine;

N-(4-cyclohexylphenyl)-2-[(2R)-2-methylmorpholin-4-yl]-8-oxo-8lambda~5~-pyrido[2,3-d]pyrimidin-4-amine;

N-(4-cyclohexylphenyl)-6-ethyl-2-[(2R)-2-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-4-amine;

4-[(4-cyclohexylphenyl)amino]-2-[(2R)-2-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidine-6-carbonitrile;

methyl 4-[(4-cyclohexylphenyl)amino]-2-[(2R)-2-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidine-6-carboxylate;

4-[(4-cyclohexylphenyl)amino]-2-[(2R)-2-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidine-6-carboxylic acid;

4-[(4-cyclohexylphenyl)amino]-2-[(2R)-2-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidine-6-carboxamide;

4-[(4-cyclohexylphenyl)amino]-2-(2-cyclopropylmorpholin-4-yl)pyrido[2,3-d]pyrimidine-6-carboxamide;

N-(4-cyclohexylphenyl)-6-methoxy-2-[(2R)-2-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-4-amine;

N-{4-[(4-cyclohexylphenyl)amino]-2-[(2R)-2-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-6-yl}acetamide;

N~4~-(4-cyclohexylphenyl)-2-[(2R)-2-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidine-4,6-diamine;

N-(4-cyclohexylphenyl)-2-(morpholin-4-yl)-6-(propan-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-amine;

N-(4-cyclohexylphenyl)-2-[(2R)-2-methylmorpholin-4-yl]-6-(propan-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-amine;

2-{4-[(4-cyclohexylphenyl)amino]-2-(3,6-dihydro-2H-pyran-4-yl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl}-N,N-dimethylacetamide;

N-(4-cyclohexylphenyl)-2-(2-cyclopropylmorpholin-4-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-amine;

2-(morpholin-4-yl)-6-(propan-2-yl)-4-{[4-(thiophen-2-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one; and

2-(morpholin-4-yl)-6-(propan-2-yl)-4-{[4-(thiophen-3-yl)phenyl]amino}-5,6-dihydro-7H-pyrrolo[3,4-d]pyrimidin-7-one.

24. A pharmaceutical composition which comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 23, and at least one pharmaceutically acceptable excipient.

25. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 23, for use in therapy.

26. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 23, for use in the treatment of a neurological disorder.

27. Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 23, for the manufacture of a medicament for the treatment of neurological disorder.

28. A compound for use or use, as claimed in claim 26 or 27, wherein the neurological disorder is selected from epilepsy, pain, autism spectrum disorders, cognition disorder, anxiety and amyotrophic lateral sclerosis.